Medtronic wins FDA clearance for its Hugo surgical robot in urology, opening a US challenge to Intuitive's 10,763 da Vinci systems

Medtronic said on December 3, 2025 that the US Food and Drug Administration had cleared its Hugo robotic-assisted surgery (RAS) system for urologic procedures, giving the medical technology group its first commercial footing in the United States for a soft-tissue surgical robot. The decision covers prostatectomy, nephrectomy and cystectomy, three operations that Medtronic estimates add up to about 230,000 procedures a year in the US.

The FDA's premarket database lists the clearance as 510(k) number K250725, filed by Covidien LLC of North Haven, Connecticut. The agency received the submission on March 10, 2025 and found the device substantially equivalent on December 3, a review of 268 days under the traditional pathway with no third-party reviewer. The system sits under product code SCV, which the FDA describes as a modular electromechanical surgical system, and the record cites clinical trial NCT05696444.

That trial is Expand URO, the investigational device exemption study Medtronic calls the largest ever completed for multi-port robotic urologic surgery in the US. According to results Medtronic released at the American Urological Association meeting in Las Vegas on April 26, 2025, the study enrolled 137 patients at six US hospitals, operated on by 11 surgeons. The cases split into 55 prostatectomies, 53 nephrectomies and 29 cystectomies, and the average patient was 63 years old.

The company reported a surgical success rate of 98.5%, against a performance goal of 85%. Rates of grade 3 or higher complications were 3.7% for prostatectomy and 1.9% for nephrectomy, each measured against a goal of 20%, and 17.9% for cystectomy against a goal of 45%. Two cases were converted to another technique, one for a device reason and one because of patient anatomy, and about 98% of patients completed 30-day follow-up, Medtronic said.

Medtronic's pitch rests on the hardware layout. Hugo uses an open surgeon console, which the company says improves situational awareness, reduces physical strain and makes training easier for the operating team. Its robotic arms are modular, so a hospital can move them between rooms and share them across sites. The system also connects to Medtronic's Touch Surgery software, which offers pre-operative training, remote tele-proctoring and AI-generated case reviews after surgery. “This is an incredibly exciting day for healthcare in the United States,” said Rajit Kamal, vice president and general manager of Robotic Surgical Technologies in Medtronic's Surgical business. Dr. James Porter, the unit's chief medical officer for robotic and digital technologies, called Hugo “a new and exciting approach to robotic-assisted surgery.”

The US market is the last major one Hugo has entered. Medtronic said the system had already been used in tens of thousands of urologic, gynecologic and general surgery procedures in more than 30 countries on five continents. The company, headquartered in Galway, Ireland, employs more than 95,000 people. In its fiscal second quarter, reported on November 18, 2025, it posted revenue of $8.961 billion and organic growth of 5.5%, but its Surgical and Endoscopy division, where Hugo sits, grew only 1.1% organically to $1.679 billion.

The incumbent is far larger in robotics. Intuitive reported third-quarter 2025 revenue of $2.51 billion, up 23%, on October 21, 2025. Its da Vinci procedures rose about 19% year on year, it placed 427 da Vinci systems in the quarter, 240 of them the new da Vinci 5, and its installed base reached 10,763 da Vinci systems at September 30, 2025. Britain's CMR Surgical reached the US earlier, winning FDA marketing authorisation for its Versius system through the De Novo route on October 14, 2024, but only for gallbladder removal; CMR said at the time that Versius had completed more than 26,000 procedures worldwide.

The regulatory route matters for what comes next. A 510(k) clearance means the FDA judged the device substantially equivalent to one already on the market, while a De Novo grant, the path CMR took, creates a new classification for a device with no suitable predicate. Hugo is a multi-port system, meaning each instrument enters the body through its own small incision on its own arm, the same broad approach used by the multi-port da Vinci models. Medtronic now needs separate clearances to use it in other specialties, and it has said general surgery and gynecology indications are expected to follow. Its November results said the Enable Hernia Repair study had met its safety and effectiveness endpoints and that the Embrace Gynecology US pivotal study had started.

For US hospitals the clearance creates a second large supplier for urologic robotics, a field in which robot choice also locks in instruments, service and training for years. Medtronic did not disclose pricing, launch sites, placement targets or how many systems it expects to ship in its current fiscal year. Those numbers, together with whether surgeons trained on da Vinci are willing to switch consoles, will decide how much share Hugo can take.

The main risks are scope and speed. Urology is a narrow first indication compared with general surgery, which CMR's own figures suggest remains lightly penetrated by robots in the US, and Intuitive is upgrading its base to da Vinci 5 at the same time. Medtronic also has to show that Hugo can lift growth in a surgical division that is expanding at about 1% organically. Investors should watch Medtronic's fiscal third-quarter report covering the quarter that ends in January 2026, Intuitive's full-year 2025 results in January 2026 and the FDA's decision on a general surgery indication.